How to select targeted therapy in renal cell cancer

Annals of Oncology

Volumn 21, Issue SUPPL. 7, 2010, Pages

  Escudier, B ^a   Albiges, L ^a   Blesius, A ^a   Loriot, Y ^a   Massard, C ^a   Fizazi, K ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Antiangiogenic; MTOR inhibitor; Renal cell carcinoma; Sequential therapy; TKI

Indexed keywords

BEVACIZUMAB; CALCIUM; EVEROLIMUS; HEMOGLOBIN; INTERFERON; LACTATE DEHYDROGENASE; PAZOPANIB; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

CONFERENCE PAPER; DRUG EFFICACY; HISTOLOGY; HUMAN; KIDNEY CARCINOMA; METASTATIC RENAL CELL CARCINOMA; MOLECULARLY TARGETED THERAPY; NEPHRECTOMY; PATIENT SELECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; TREATMENT INDICATION;

EID: 78649379884     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq371     Document Type: Conference Paper

References (23)

1. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125-134.
2. Motzer R, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-124.
3. Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 2271-2281.
4. Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007; 370: 2103-2111.
5. Motzer RJ, Escudier B, Oudard S et al. Everolimus for advanced renal cell carcinoma. Lancet 2008; 372: 449-456.
6. Sternberg C, Davis ID, Mardiak J et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010; 28: 1061-1068.
7. Motzer RJ, Bacik J, Schwartz LH et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 2004; 22: 454-463.
8. Heng DY, Xie W, Regan MM et al. Prognostic factors for overall survival (OS) in patients with metastatic renal cell carcinoma (RCC) treated with vascular endothelial growth factor (VEGF)-targeted agents: results from a large multicenter study. J Clin Oncol 2009; 27 (Suppl): abstract 5041.
9. Patil S, Figlin RA, Hutson TE et al. Prognostic factors for overall survival with sunitinib as first-line therapy in patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2009; 27 (Suppl): abstract 5042.
10. Bellmunt J, Guix M. The medical management of metastatic renal cell carcinoma: integrating new guidelines and recommendations. BJU Int 2009; 103: 572-577.
11. Bellmunt J, Negrier S, Escudier B et al. The medical treatment of metastatic renal cell cancer in the elderly: position paper of a SIOG Taskforce. Crit Rev Oncol Hematol 2009; 69: 64-72.
12. Thomas AA, Rini BI, Stephenson AJ et al. Surgical resection of renal cell carcinoma after targeted therapy. J Urol 2009; 182: 881-886.
13. Flanigan RC, Salmon SE, Blumenstein BA et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001; 345: 1655-1659.
14. Mickisch GH, Garin A, van Poppel H et al. European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001; 358: 966-970.
15. Choueri T, Plantade A, Elson P et al. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol 2008; 26: 127-131.
16. Escudier B, Szczylik C, Hutson TE et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon alpha-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27: 1280-1289.
17. Atkins MB, Hidalgo M, Stadler WM et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004; 22: 909-918.
18. Motzer RJ, Rini BI, Bukowski RM et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006; 295: 2516-2524.
19. Rini BI, Michaelson MD, Rosenberg JE et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 2008; 26: 3743-3748.
20. Negrier S, Escudier B, Gomez F et al. Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Francais d'Immunotherapie. Ann Oncol 2002; 13: 1460-1468.
21. Escudier B, Gross Goupil M, Massard C et al. Sequential therapy in renal cell carcinoma. Cancer 2009; 115 (10 Suppl): 2321-2326.
22. Escudier B, Bellmunt J, Négrier S et al. A phase III trial of bevacizumab plus interferon-a2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 2010; 28: 2144-2150.
23. Atkins MB, Choueri T, Cho D et al. Treatment selection for patients with metastatic renal cell carcinoma. Cancer 2009; 115 (10 Suppl): 2327-2333.